On 16 August, Ashish Adukia was appointed as the global Chief Financial Officer (CFO), and key managerial personnel of Cipla Ltd approval was given by the board of directors (BOD). Dinesh Jain, the new appointment, will relieve the additional responsibility of the interim CFO. He will continue with the company as senior vice president and head of corporate finance. Ashish Adukia is a Chartered Accountant (CA) and MMS (Finance) from JBIMS. In 2017, he featured in Fortune India’s 40 under 40 lists.

• IREDA Shares Skyrocketed 11% on Receiving Navratna Status 
• Glenmark Pharma Shares Gain 1% on Receiving USFDA Approval 
• Stocks Under F&O Ban: Vodafone Idea
• Stocks in Focus: Vodafone Idea, Maruti Suzuki, ICICI Bank, and Others
• Vedanta Outlook for the Week (April 29, 2024 – May 03, 2024)

Cipla is a global pharmaceutical company focused on agile and sustainable growth, complex generics, and deepening portfolio in our home markets of India, South Africa, North America, and key regulated and emerging markets.

The consolidated net profit of Cipla Ltd has slipped 4 per cent to Rs 686.40 crore on a 2.3 per cent decline in total revenue from operations to Rs 5,375.19 crore in Apr-Jun quarter of FY23 over the same period of last year. Also, the stock of Cipla Ltd went down by 0.18 per cent to Rs 1,032 on the Bombay Stock Exchange (BSE).